

TABLE

Table. Clinical characteristics of post-vaccine and non-vaccine associated GBS cases reported to IMPACT and CPSP, respectively.

	Post-vaccine cases N=24		Non-vaccine associated cases N=222		P*
	n	%	n	%	
Male sex	13	54	137	61	0.81
Age at onset					
median, range (in years)	5.9	0.4-14.5	5	0.1-14.8	-
Normal Neuro history	24	100	201	91	0.24
Fever	8	33	48	22	0.19
Respiratory symptoms	11	46	134	60	0.17
Neuro features					
weakness	24	100	222	100	-
Areas of weakness					<0.001
Quadrilateral	6	25	153	70	
Legs, bilateral	9	38	56	26	
Arms, bilateral	1	4	2	1	
Legs/Arms, unilateral	1	4	3	1	
Other†	10	42	39	18	
Cranial nerve involvement	8	33	52	23	0.14
Cerebrospinal fluid analysis‡					0.5
normal	2	8	25	11	
abnormal	20	83	156	70	
not done	2	8	40	18	
unknown	0	0	1	0.4	
Neuroimaging‡					0.15
normal	13	56	87	39	
abnormal	7	29	46	22	
not done	4	17	78	35	
unknown	0	0	11	5	
Hospitalized	24	100	221	99	>0.99
Length of hospital stay (median, range), in days	7	2-58	7	1-105	-
Microbiologically-confirmed infection	5	21	23	11	0.17
Organisms Identified¶	EBV <i>Mycoplasma</i>		EBV (4 cases) <i>M. pneumoniae</i>		herpes simplex (3) <i>Chlamydia</i>

<i>pneumoniae</i>	(4)	<i>pneumoniae</i>
VZV	VZV (4)	coronavirus
CMV	influenza (4)	HHV-7
enterovirus	CMV (3)	parainfluenza
	adenovirus (3)	RSV

CMV, cytomegalovirus; EBV, Epstein-barr virus; HHV-7, human herpes virus-7; RSV,

respiratory syncytial virus; VZV, varicella-zoster virus

* χ^2 or Fisher exact test

†Respiratory muscles (CPSP only), neck, trunk, generalized (IMPACT only)

‡Abnormal denotes any value outside of the normal range or any abnormality noted on the radiology report

¶Some patients had more than one organism identified